Table 1.
Ongoing clinical trials
| Status/Phase | Study Title | Interventions | NCT Number |
|---|---|---|---|
| N/A/I | Nivolumab With DC Vaccines for Recurrent Brain Tumors | Nivolumab + dendritic cell vaccine | NCT02529072 |
| 1/II | Autologous Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients with Glioblastoma | ALECSAT + radiotherapy + temozolomide | NCT02799238 |
| 1/I | Vaccine Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme | Tetanus toxoid + therapeutic autologous dendritic cells + therapeutic autologous lymphocytes | NCT00639639 |
| 1/II | Pembrolizumab in Treating Patients with Recurrent Glioblastoma | Pembrolizumab | NCT02337686 |
| 1/I/II | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | DNA-based cancer vaccine INO-5401(hTERT, WT1, and PSMA) + INO-9012 (IL-12) + cemiplimab + radiotherapy + temozolomide | NCT03491683 |
| 1/I | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | DNX-2440 (Oncolytic Adenovirus) | NCT03714334 |
| 1/I | A Pilot Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | Pembrolizumab | NCT02852655 |
| 1/II | Avelumab in Patients with Newly Diagnosed Glioblastoma Multiforme | Avelumab | NCT03047473 |
| 1/II | Dendritic Cell Vaccine for Patients with Brain Tumors | Autologous tumor lysate-pulsed DC vaccination + adjuvant polyICLC | NCT01204684 |
| 1/II | Avelumab With Hypofractionated Radiation Therapy in Adults with Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | Avelumab + hypofractionated radiation therapy (HFRT) | NCT02968940 |
| 1/II | Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Recurrent or Progressive Glioblastoma | MDNA55 (a fusion protein comprising a genetically engineered Interleukin-4 (IL-4) linked to a modified version of the Pseudomonas aeruginosa exotoxin A (PE)) | NCT02858895 |
| 1/I | Phase I Study of a Dendritic Cell Vaccine for Patients with Either Newly Diagnosed or Recurrent Glioblastoma | Dendritic cell vaccine + radiotherapy + temozolomide ± bevacizumab | NCT02010606 |
| 1/II | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients with Recurrent Malignant Glioma | Durvalumab + tremelimumab | NCT02794883 |
| 1/II | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | DNX-2401 (Oncolytic adenovirus) + pembrolizumab | NCT02798406 |
| 1/I | A Phase I Study of AdV-tk + Prodrug Therapy in Combination with Radiation Therapy for Pediatric Brain Tumors | AdV-tk (an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene) + valacyclovir + radiation | NCT00634231 |
| 2/II | Bevacizumab with or Without Trebananib in Treating Patients With Recurrent Brain Tumors | Bevacizumab + trebananib | NCT01609790 |
| 2/II | Phase 2 Study of Durvalumab (MEDI4736) in Patients with Glioblastoma | Durvalumab + radiotherapy + temozolomide + bevacizumab | NCT02336165 |
| 3/II/III | Proteome-Based Personalized Immunotherapy of Glioblastoma | Dendritic vaccine + allogeneic hematopoietic stem cells + cytotoxic lymphocytes | NCT01759810 |
| 3/I | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | Antigen-specific IgT cells | NCT03170141 |
| 4/I/II | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients | Dendritic cell vaccine + temozolomide | NCT02649582 |
| 4/II/III | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy | Dendritic cell immunization + adjuvant temozolomide | NCT03548571 |
| 4/II | Immunotherapy Targeted Against Cytomegalovirus in Patients with Newly-Diagnosed WHO Grade IV Unmethylated Glioma | Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF + temozolomide + tetanus–diphtheria toxoid (Td) 111-Indium-labeling of Cells for in vivo Trafficking Studies |
NCT03927222 |
| 4/II | V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer | V-Boost (an oral tablet which contains specially formulated hydrolyzed GBM antigens along with alloantigens) | NCT03916757 |
| 4/II | Study of DC Vaccination Against Glioblastoma | Dendritic cell vaccine + radiotherapy + temozolomide | NCT01567202 |
| 4/I | Pembrolizumab and Vorinostat Combined with Temozolomide for Newly Diagnosed Glioblastoma | Pembrolizumab + vorinostat + temozolomide + radiotherapy | NCT03426891 |
| 4/III | An Investigational Immuno-Therapy Study of Temozolomide Plus Radiation Therapy with Nivolumab or Placebo, for Newly Diagnosed Patients with Glioblastoma (GBM, a Malignant Brain Cancer) | Nivolumab + temozolomide + radiotherapy | NCT02667587 |
| 4/III | An Investigational Immuno-Therapy Study of Nivolumab Compared to Temozolomide, Each Given with Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | Nivolumab + temozolomide + radiotherapy | NCT02617589 |
| 4/I | Biomarker-Driven Therapy Using Immune Activators with Nivolumab in Patients with First Recurrence of Glioblastoma | Nivolumab + anti-GITR monoclonal antibody MK-4166 + IDO1 inhibitor INCB024360 + ipilimumab | NCT03707457 |
| 4/II | Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) | Pembrolizumab + HSPPC-96 (an autologous tumor-derived heat shock protein peptide-complex) + temozolomide | NCT03018288 |
| 4/I | Nivolumab, BMS-986205, and Radiation Therapy with or without Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma | IDO1 Inhibitor BMS-986205 + nivolumab + radiation therapy + temozolomide | NCT04047706 |
| 4/I | Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | Dendritic cell tumor cell lysate vaccine + pembrolizumab + poly ICLC | NCT04201873 |
| 4/I | Genetically Modified T-cells in Treating Patients with Recurrent or Refractory Malignant Glioma | IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing Autologous T lymphocytes | NCT02208362 |
| 4/I | IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells with or without Nivolumab and Ipilimumab in Treating Patients with Recurrent or Refractory Glioblastoma | IL13Ralpha2-specific hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing autologous TN/MEM cells + ipilimumab + nivolumab | NCT04003649 |
| 4/I/II | Atezolizumab in Combination with Temozolomide and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma | Atezolizumab + radiation therapy + temozolomide | NCT03174197 |
| 4/II | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients with Metastatic Cancer | Young TIL + aldesleukin + cyclophosphamide | NCT01174121 |
| 4/I/II | NCT Neuro Master Match - N²M² (NOA-20) | APG101 (a soluble CD95-Fc fusion protein) or alectinib or idasanutlin or atezolizumab or vismodegib or palbociclib | NCT03158389 |
| 4/II | Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma | autologous, tumor lysate-loaded, mature dendritic cells (DC) + radiation therapy + temozolomide | NCT03395587 |
| 4/I | Memory-Enriched T Cells in Treating Patients with Recurrent or Refractory Grade III-IV Glioma | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes + CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes | NCT03389230 |
| 4/I/II | A Phase I/IIa Study Evaluating Temferon in Patients with Glioblastoma and Unmethylated MGMT | Temferon | NCT03866109 |
| 4/I | Phase I EGFR BATs in Newly Diagnosed Glioblastoma | EGFR BATs + radiation therapy + temozolomide | NCT03344250 |
| 4/I | Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients with Glioblastoma Multiforme | Autologous TIL+ PD1-TIL | NCT03347097 |
| 4/II | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | Indoximod + partial radiation or full-dose radiation | NCT04049669 |
| 4/I | Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1) | GM-CSF + Poly I:C or CAR-T or TCR-T + radiation | NCT03392545 |
| 4/I | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | Avelumab + MRI-guided LITT therapy | NCT03341806 |
| 4/I | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma | M032 (NSC 733972) (a second-generation oncolytic herpes simplex virus (oHSV)) | NCT02062827 |
| 4/II | Non-Viral TCR Gene Therapy | fludarabine + cyclophosphamide + aldesleukin + sleeping beauty transposed PBL | NCT04102436 |
| 4/I | Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | Poly-ICLC + tumor treating fields + peptides vaccine | NCT03223103 |
| 4/I | A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects with Recurrent Glioblastoma Multiforme (GBM) | EGFR(V)-EDV-Dox (a bacterially derived minicell which packages a toxic payload, doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb)) | NCT02766699 |
| 4/II | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People with Metastatic Cancer | Cyclophosphamide + fludarabine + aldesleukin + individual patient TCR-Transduced PBL + pembrolizumab | NCT03412877 |
| 4/I/II | Dose-Escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients with Glioblastoma | GX-I7 (a protein drug recombining human IL-7 and hybrid Fc (hyFc)) | NCT03619239 |
| 4/I/II | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | VBI-1901 (a polyvalent therapeutic vaccine against cytomegalovirus antigen gB and pp65) + GM-CSF | NCT03382977 |
| 4/I | Trial of C134 in Patients with Recurrent GBM | C134 (a cancer killing virus (HSV-1)) | NCT03657576 |
| 4/I | GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas | AdV-tk + valacyclovir + radiation + temozolomide + nivolumab | NCT03576612 |
| 4/I | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients with Progressive Primary Malignant Brain Tumors | Indoximod + temozolomide + conformal radiation + cyclophosphamide + cyclophosphamide | NCT02502708 |
| 4/I | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | rQNestin (an oncolytic viral vector made from the herpes simplex virus type 1 (HSV1)) + cyclophosphamide | NCT03152318 |
| 4/I | Phase 1b Study PVSRIPO on Recurrent Malignant Glioma in Children | polio/rhinovirus recombinant (PVSRIPO) | NCT03043391 |
| 4/I | HSV G207 in Children with Recurrent or Refractory Cerebellar Brain Tumors | G207 (an oncolytic herpes simplex virus-1 (HSV)) | NCT03911388 |
| 4/I | HSV G207 Alone or With a Single Radiation Dose in Children with Progressive or Recurrent Supratentorial Brain Tumors | G207 (an oncolytic herpes simplex virus-1 (HSV)) + radiation | NCT02457845 |
Status number shows: 1 = Active, not recruiting; 2 = Active, not recruiting / has results; 3 = Enrolling by invitation; 4 = Recruiting; N/A = Not available.